LTBP4 is a key extracellular matrix protein that regulates transforming growth factor-beta (TGF-β) signaling by maintaining it in a latent state through disulfide bond interactions with the latency-associated peptide 1. Beyond TGF-β regulation, LTBP4 exhibits TGF-β-independent activities in stabilizing microfibril bundles and regulating elastic fiber assembly 1. LTBP4 protects against renal fibrosis by maintaining mitochondrial function and promoting angiogenesis; LTBP4 deficiency increases acute kidney injury severity and progression to chr19 kidney disease through increased mitochondrial fragmentation, oxidative stress, and inflammation 2. In Duchenne muscular dystrophy (DMD), LTBP4 emerges as a critical disease modifier; specific LTBP4 polymorphisms associate with ambulation outcomes, with the hinge region regulating TGF-β release and fibrosis development 34. LTBP4 SNP rs10880 predicts loss of ambulation in DMD patients 5. Additionally, LTBP4 is prioritized at aortic diameter genome-wide association loci in fibroblasts 6, and its dysregulation in blood associates with spinocerebellar ataxia type 3 disease progression 7. Mutations in LTBP4 cause autosomal recessive cutis laxa type 1C, characterized by skin laxity, pulmonary emphysema, and cardiac valve disease 8.